Loading...
Market
Will Brenus Pharma complete Phase 1 clinical trials for its precision cancer vaccine by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Official press release from Brenus Pharma or regulatory filings
Story
Brenus Pharma Raises €22.2 Million ($25 Million) to Advance Cancer Vaccine Trials
Sep 19, 2024, 08:13 AM
Brenus Pharma, a French biotech company based in Lyon, has successfully raised €22.2 million ($25 million) in a Series A funding round. The funds will be used to accelerate the clinical trials of its precision cancer vaccines. The funding round was led by Angelor, a prominent investment firm. Brenus Pharma specializes in developing innovative cancer vaccines aimed at improving patient outcomes.
View original story
Similar markets
Yes • 50%
No • 50%
Successful • 33%
Partially Successful • 33%
Unsuccessful • 33%
Yes • 50%
No • 50%
Less than €10M • 25%
Between €10M and €20M • 25%
Between €20M and €30M • 25%
More than €30M • 25%
Yes • 50%
No • 50%
Successful with significant improvement in survival rates • 25%
Successful with moderate improvement in survival rates • 25%
No significant improvement in survival rates • 25%
Trial halted due to adverse effects • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
